In older patients with myelodysplastic syndrome (MDS) refractory to hypomethylating agents, treatment with the orally administered nucleoside analogue sapacitabine resulted in 1-year survival rates of 29-35%, a randomized phase 2 study presented at the 52nd American Society of Hematology Meeting and Exposition has found.
Sign in with your MPR account
Keep me signed in Forgot your password?
REGISTER FOR FREE WITH A MPR ACCOUNT
Enter your MPR registration email address to receive a new password.